Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Contributed by: GlobeNewswire

Images

GlobeNewswire associated0
GlobeNewswire associated1

Tags

biotechnology

More Like This

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

PR Newswire associated0

Alamar Biosciences Launches Certified Service Provider Program to Expand Access to NULISA technology for Academic and Biopharmaceutical Researchers

PR Newswire associated0

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

Alamar Biosciences logo (Graphic: Business Wire)

ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

PR Newswire associated0

Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120

PR Newswire associated0

Alamar Biosciences Achieves ISO 13485 Certification, Demonstrating its Commitment to Quality and Safety

PR Newswire associated0

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays